查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863412

按产品分类、治疗领域、通路、给药途径和最终用户分類的中轴型脊椎关节炎市场－2025-2032年全球预测

Axial Spondyloarthritis Market by Product Class, Treatment Line, Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，中轴型脊椎关节炎市场将成长至 103.2 亿美元，复合年增长率为 7.73%。

主要市场统计数据
基准年 2024 56.8亿美元
预计年份：2025年 61.2亿美元
预测年份：2032年 103.2亿美元
复合年增长率 (%) 7.73%

中轴型脊椎关节炎的全面概述：重点介绍临床复杂性、诊断障碍、治疗模式以及影响相关人员决策的不断变化的优先事项

中轴型脊椎关节炎（ASA）是一种复杂的慢性发炎性疾病，主要涉及脊椎和骶髂关节，导致许多患者出现疼痛、僵硬和长期功能障碍。临床医师面临许多诊断挑战，包括症状的异质性、与机械性腰痛的重迭，以及需要将临床评估与影像生物标记资讯结合。免疫学和分子医学的进步正在改变人们对该疾病的临床认识，但在早期检测、治疗顺序和长期管理策略方面仍然存在挑战。

变革性的临床、医疗服务和价值驱动型进展正在汇聚，重新定义中轴型脊椎关节炎在整个医疗路径中的诊断、治疗和管理方式。

中轴型脊椎关节炎的治疗格局正在经历变革时期，这主要得益于标靶治疗的突破、不断更新的安全性数据以及患者期望的改变。白细胞介素-17抑制剂和Janus激酶抑制剂的出现，拓展了肿瘤坏死因子抑制剂以外的治疗选择，迫使临床医生重新思考治疗顺序和个人化策略。同时，不断累积的真实世界数据和註册登记数据揭示了不同患者亚群之间的治疗反应差异，因此需要开发更精细的治疗流程，并将重点放在长期疾病控製而非暂时缓解症状上。

为应对关税和全球贸易中断带来的成本压力，以及由此对治疗取得造成的影响，供应链韧性、临床营运和合约策略正在接受审查。

贸易政策的转变，包括2025年生效的关税调整，正为用于治疗中轴型脊椎关节炎的生技药品和小分子药物的全球供应链带来新的复杂性。由于原料药和成品进口关税的提高，导致到岸成本上升，并对现有定价协议构成压力，製药企业和经销商被迫重新评估筹资策略。儘管一些公司历来采用分散式製造地模式，但关税的实施正在加速关于近岸外包、双重采购和策略性库存布局的讨论，以确保治疗的连续性并最大限度地减少对关键患者群体的影响。

按产品分类、治疗领域、分销管道、给药途径和最终用户进行細項分析，可以揭示可用于临床和商业策略的可操作差异化因素。

详细的市场細項分析揭示了不同产品类别、治疗方案、分销管道、给药途径和终端用户环境之间的显着动态，这些差异对临床和商业性选择产生重大影响。在产品类别中，传统的缓解疾病抗风湿药物（DMARDs），包括羟氯喹、胺基甲基叶酸和柳氮磺胺吡啶等药物，被定位为特定患者群体的基础治疗方法，尤其适用于临床医生旨在控制合併症或限制生技药品製剂暴露的情况。以Brodalumab 、ixekizumab和sectinimab为代表的IL-17抑制剂，在轴性发炎生物标记和临床表型提示高反应可能性的Janus，已建立起独特的利基市场。 Janus激酶抑制剂，包括filgotinib、tofacitinib和Upadacitinib ，是口服标靶治疗，适用于寻求便利性和快速症状控制的患者。

区域间在监管、支付模式和医疗基础设施方面的差异，造成了不同的医疗服务取得管道，需要客製化的证据和分销策略。

区域趋势反映了流行病学、法规环境、支付方框架和医疗服务基础设施的差异，这些差异影响着医疗服务的可近性和策略。在美洲，医疗系统采用公私支付机制相结合的方式，并强调基本契约和专科药房网络，从而促进患者获得先进的生技药品和口服标靶药物。该地区越来越多地利用真实世界数据（RWD）倡议和患者登记系统来支持价值提案和报销谈判，同时远端医疗的扩展也加强了远端监测和依从性干预。

竞争优势依赖差异化的证据、整合的患者权益倡导、可靠的供应以及贯穿整个治疗生命週期的策略伙伴关係。

中轴型脊椎关节炎领域的竞争格局由成熟的生技药品製剂产品线、新兴的标靶分子药物以及提供输注、配送和患者支持的专业服务供应商共同构成​​。现有的肿瘤坏死因子抑制剂产品组合继续利用多年的临床经验和广泛的安全性数据，而包括白细胞介素-17抑制剂和Janus激酶抑制剂在内的新型药物类别则致力于在特定患者群体中展现临床差异化优势，并提供更便捷的给药途径。

为了将临床创新转化为可持续的患者影响，应优先考虑综合证据产生、加强供应链韧性、与支付方合作、定製商业化和教育。

为因应临床复杂性、政策变化和商业性压力，产业领导者应优先采取一系列切实有效且影响深远的行动。首先，透过投资比较疗效研究、真实世界资料收集和病患报告结局研究，使证据生成与监管机构和支付方的期望保持一致，从而明确长期获益和安全性。其次，透过製造地多元化、策略性库存管理和物流伙伴关係，增强供应链韧性，以减轻贸易政策和关税相关干扰的影响。

我们以证据为导向的多学科调查方法，结合同行评审的科学论文、专家访谈、监管分析和营运情报，从而得出可操作的临床和商业性见解。

本研究综述基于多学科方法，整合了初级和二级研究、专家咨询以及系统性证据审查，对中轴型脊椎关节炎进行了全面的观点。疾病生物学、治疗机制和安全性概况的基础建立在临床和科学文献、指南文件、监管沟通以及同行评审研究的基础上。此外，也透过对临床医生、专科药剂师和市场进入负责人的专案访谈，补充了对真实世界临床实践模式、诊断流程以及医保谈判趋势的了解。

整合临床进展、营运韧性与策略伙伴关係，打造协调一致的方案，加速以病人为中心的治疗效果和永续的医疗服务取得。

中轴型脊椎关节炎既带来了持续的挑战，也为临床创新和策略行动提供了明确的机会。儘管诊断延迟和患者反应的差异性持续阻碍着治疗进程，但包括生技药品和标靶药物在内的治疗选择不断扩展，为实现持久的疾病控制和改善长期功能开闢了新的途径。政策趋势和贸易动态虽然增加了营运的复杂性，但也促使企业在供应链韧性、生产多元化和透明合约等方面进行有利可图的投资。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 对于第一线TNF抑制剂无效的非放射性中轴型脊椎关节炎患者，JAK抑制剂的快速应用
  • 增加对生物标记驱动的诊断技术的投资，以早期发现中轴型脊椎关节炎的进展
  • 扩展远端医疗平台，整合病患报告结果，用于远距监测疾病活动
  • 在研产品测试中，针对TNF和IL-17通道的双特异性抗体候选药物涌现。
  • 来自Etanercept和Adalimumab单抗生物相似药日益激烈的竞争正在影响定价和市场进入策略。
  • 引入定量MRI评分演算法以改善早期诊断和治疗分层
  • 采用基于价值的合约模式与支付方合作，重点关註生技药品在治疗中轴型脊椎关节炎的长期功能性疗效。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类别分類的中轴型脊椎关节炎市场

  • 传统DMARDs
    • 羟氯喹
    • 胺基甲基叶酸
    • 柳氮磺胺吡啶
  • IL-17抑制剂
    • Brodalumab
    • 伊克珠单抗
    • 塞克替尼单抗
  • JAK抑制剂
    • 菲戈替尼
    • 託法替尼
    • Upadacitinib
  • 非类固醇消炎剂（NSAIDs）
    • 双氯芬酸钠
    • Ibuprofen
    • 萘普生
  • TNF抑制剂
    • Adalimumab
    • 赛妥珠单抗
    • Etanercept
    • 戈利木单抗
    • Infliximab

9. 中轴型脊椎关节炎市场（依治疗线划分）

  • 一线治疗
  • 二线治疗
  • 三线治疗

第十章 中轴型脊椎关节炎市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 中轴型脊椎关节炎市场（依给药途径划分）

  • 注射
  • 静脉注射
  • 口服

第十二章 轴性脊椎关节炎市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 专科诊所

第十三章 中轴型脊椎关节炎市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 轴性脊椎关节炎市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国中轴型脊椎关节炎市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Novartis AG
    • Janssen BIoTech, Inc.
    • Eli Lilly and Company
    • UCB SA
    • Amgen Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
Product Code: MRR-5C6F41F5AF7D

The Axial Spondyloarthritis Market is projected to grow by USD 10.32 billion at a CAGR of 7.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.68 billion
Estimated Year [2025] USD 6.12 billion
Forecast Year [2032] USD 10.32 billion
CAGR (%) 7.73%

A comprehensive orientation to axial spondyloarthritis highlighting clinical complexity, diagnostic barriers, treatment paradigms, and the evolving priorities shaping stakeholder decision-making

Axial spondyloarthritis represents a complex chronic inflammatory condition that primarily affects the spine and sacroiliac joints, producing pain, stiffness, and long-term functional impairment for many patients. Clinicians face diagnostic challenges driven by heterogenous symptom presentation, overlaps with mechanical back pain, and the need to combine clinical assessment with imaging and biomarker information. Advances in immunology and molecular medicine are reshaping clinical understanding, yet gaps persist in early identification, therapeutic sequencing, and long-term management strategies.

Patients commonly navigate protracted pathways before receiving a definitive diagnosis, which influences both clinical outcomes and healthcare resource utilization. In parallel, therapeutic decision-making increasingly integrates targeted biologics and small molecules alongside conventional disease-modifying agents and symptomatic management with nonsteroidal anti-inflammatory drugs. The commercial and clinical landscape is evolving as new mechanisms of action demonstrate differential efficacy across patient phenotypes, safety profiles, and routes of administration. Stakeholders must therefore balance efficacy, tolerability, patient preference, and delivery models to optimize adherence and outcomes.

This introduction sets the stage for a detailed exploration of transformative shifts, policy influences, segmentation-driven opportunity areas, regional dynamics, competitive interplay, and actionable recommendations. The objective is to equip clinicians, payers, life sciences executives, and distribution leaders with a concise yet comprehensive orientation to the current state and near-term inflection points in axial spondyloarthritis management.

Transformative clinical, delivery, and value-based evolutions are converging to redefine how axial spondyloarthritis is diagnosed, treated, and managed across care pathways

The treatment landscape for axial spondyloarthritis has entered a period of transformative change driven by breakthroughs in targeted therapies, evolving safety evidence, and shifts in patient expectations. The emergence of interleukin-17 inhibitors and Janus kinase inhibitors has broadened therapeutic options beyond tumor necrosis factor inhibitors, prompting clinicians to rethink sequencing and personalization strategies. At the same time, growing real-world evidence and registry data have begun to delineate differential responses among patient subgroups, prompting more nuanced treatment algorithms and a stronger focus on long-term disease control rather than transient symptom relief.

Concurrently, care delivery models are adapting to patient preferences for convenience and continuity. The proliferation of oral targeted therapies and optimized infusion or injection delivery protocols has intensified competition across routes of administration, while digital health platforms are augmenting monitoring, adherence support, and remote consultations. Payer frameworks are responding to these clinical advances with increasingly outcome-oriented reimbursement models; value frameworks now place greater emphasis on sustained functional improvement, reduced flares, and avoidance of long-term disability.

Finally, innovation extends beyond pharmacology into diagnostics and biomarkers that aim to shorten diagnostic delay and enable precision prescribing. These diagnostic advances, paired with evolving clinical practice guidelines and multidisciplinary care pathways, are collectively reshaping how patients are identified, treated, and monitored, creating new windows for strategic investment and care model redesign.

Supply chain resilience, clinical operations, and contracting strategies are being reoriented in response to tariff-driven cost pressures and global trade disruptions affecting therapy access

Trade policy shifts, including tariff adjustments enacted in 2025, have injected new complexity into the global supply chains that underpin biologic and small molecule availability for axial spondyloarthritis. Pharmaceutical manufacturers and distributors have had to reassess sourcing strategies as increased duties on active pharmaceutical ingredients and finished product imports elevate landed costs and pressure established pricing contracts. While some firms have long maintained diversified manufacturing footprints, the tariffs have accelerated discussions around nearshoring, dual-sourcing, and strategic inventory positioning to preserve continuity of care and minimize disruption to critical therapeutic cohorts.

Clinical trial operations have also felt the ripple effects as sponsors re-evaluate site selection, import/export logistics for investigational products, and the cost calculus associated with multinational protocol execution. Regulatory authorities and ethical review boards have engaged with sponsors to ensure participant access is not compromised in cross-border studies, particularly where specialized biologic formulations require controlled temperature logistics and robust distribution partners. Health systems and payers are scrutinizing the downstream impact on formulary decisions and procurement cycles, weighing the cost pressure against clinical necessity and negotiated rebates or patient access programs.

In response, commercial teams are recalibrating contracting strategies with payers and distributors, emphasizing transparent cost drivers and supply continuity assurances. Manufacturers with integrated supply chain capabilities are better positioned to mitigate near-term volatility, while others are exploring collaborative frameworks with logistics partners to stabilize delivery timelines. Ultimately, tariff-induced pressures are catalyzing a strategic reorientation toward supply resilience, pricing transparency, and adaptive commercialization tactics that preserve patient access amid shifting trade environments.

Granular segmentation across product classes, treatment lines, channels, administration routes, and end users reveals actionable differentiation in clinical and commercial strategies

Deep segmentation analysis reveals differentiated dynamics across product classes, treatment lines, distribution channels, routes of administration, and end-user settings that materially influence clinical and commercial choices. Within product classes, conventional disease-modifying antirheumatic drugs encompass agents such as hydroxychloroquine, methotrexate, and sulfasalazine that remain foundational for certain patient profiles, particularly when clinicians aim to manage comorbid features or limit exposure to biologics. IL-17 inhibitors, represented by brodalumab, ixekizumab, and secukinumab, have carved a distinct niche where axial inflammation biomarkers and clinical phenotype suggest higher likelihood of response. Janus kinase inhibitors including filgotinib, tofacitinib, and upadacitinib provide an oral targeted option that appeals to patients seeking convenience and rapid onset of symptomatic control.

Nonsteroidal anti-inflammatory drugs such as diclofenac, ibuprofen, and naproxen continue to play a central role for symptomatic relief and flare management, while the broad class of tumor necrosis factor inhibitors, including adalimumab, certolizumab, etanercept, golimumab, and infliximab, remains a proven cornerstone for many moderate-to-severe cases. Treatment line segmentation further shapes clinical pathways: first-line approaches emphasize rapid inflammation control and functional preservation, second-line decisions reflect response durability and safety trade-offs, and third-line strategies integrate prior biologic exposure, comorbidity profiles, and tolerance history.

Distribution channel and route of administration considerations also inform adoption patterns. Hospital pharmacies and specialty clinics often manage infusion-based regimens and initial biologic initiations, whereas retail and online pharmacies facilitate maintenance dispensing, home administration, and adherence support for oral and injectable therapies. Injectable, intravenous, and oral routes each carry implications for patient convenience, monitoring requirements, and cost structures. End-user segmentation across home care, hospitals, and specialty clinics determines where education, infusion capacity, and long-term monitoring resources must be concentrated to ensure optimal outcomes. Taken together, these intersecting segmentation layers reveal clear opportunities for targeted clinical protocols, differentiated commercial approaches, and channel-specific patient support models.

Regional variations in regulation, payer models, and healthcare infrastructure create differentiated pathways to access that require customized evidence and distribution strategies

Regional dynamics reflect divergent epidemiology, regulatory environments, payer frameworks, and healthcare delivery infrastructures that shape access and strategy. In the Americas, health systems exhibit a mix of private and public payer mechanisms with an emphasis on outcomes-based contracting and specialty pharmacy networks that can facilitate access to advanced biologics and oral targeted agents. Real-world data initiatives and patient registries in this region are increasingly leveraged to support value narratives and reimbursement discussions, while telehealth expansion has strengthened remote monitoring and adherence interventions.

The Europe, Middle East & Africa region presents varied regulatory landscapes and procurement practices. In parts of Europe, centralized reimbursement deliberations and health technology assessment processes place significant weight on comparative effectiveness, quality-of-life outcomes, and long-term safety data. In the Middle East and Africa, variable infrastructure and funding models create pockets of both advanced specialty care delivery and constrained access, making partnerships with regional distributors and investment in local capacity building strategic priorities for manufacturers and service providers.

Asia-Pacific is characterized by rapid adoption of innovative therapies in certain markets, alongside distinct regulatory pathways and local manufacturing expectations in others. National strategies emphasizing domestic pharmaceutical capabilities and evolving reimbursement policies influence how novel agents are introduced and scaled. Cross-border supply chain considerations and differing clinical guideline adoption timelines further contribute to a mosaic of access and uptake patterns. Across all regions, stakeholders benefit from tailoring clinical evidence generation, market access strategies, and distribution partnerships to the specific regulatory, payer, and infrastructure realities they face.

Competitive advantage will depend on differentiated evidence, integrated patient support, supply reliability, and strategic partnerships across the therapy lifecycle

Competitive dynamics in axial spondyloarthritis are shaped by established biologic franchises, emergent targeted small molecules, and specialized service providers that support infusion, distribution, and patient support. Incumbent tumor necrosis factor inhibitor portfolios continue to leverage long-standing clinical experience and extensive safety datasets, while newer classes, including interleukin-17 inhibitors and Janus kinase inhibitors, concentrate on demonstrating clinical differentiation in specific patient cohorts and offering alternative routes of administration or dosing convenience.

Strategic imperatives for leading companies include deep investment in head-to-head and real-world comparative studies, development of robust patient support ecosystems to facilitate adherence for home-administered therapies, and expansion of manufacturing or distribution capabilities to ensure supply continuity. Partnerships between pharmaceutical sponsors and specialty pharmacy networks or infusion service providers are increasingly common as a means to streamline initiation, monitoring, and reimbursement workflows. Additionally, companies are prioritizing lifecycle management through formulation improvements, indication expansion studies, and evidence generation that supports positioning across treatment lines.

New entrants and smaller biopharma players are differentiating through niche clinical programs, biomarker-driven trials, and collaborations with diagnostic developers to enable more targeted prescribing. For commercial leaders, the ability to align clinical value messaging with payer expectations, demonstrate operational excellence in supply and distribution, and deploy digital-first patient engagement tools will determine competitive positioning and long-term success in the axial spondyloarthritis landscape.

Prioritize integrated evidence generation, supply resilience, payer collaboration, tailored commercialization, and education to convert clinical innovation into sustainable patient impact

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate clinical complexity, policy shifts, and commercial pressures. First, align evidence generation with both regulatory and payer expectations by investing in comparative effectiveness research, real-world data capture, and patient-reported outcome studies that clarify long-term benefits and safety profiles. Second, strengthen supply chain resilience through diversification of manufacturing footprints, strategic inventory management, and collaborative logistics partnerships that mitigate trade-policy and tariff-related disruptions.

Third, design tailored commercialization strategies that consider the interplay between product class, treatment line, distribution channel, and route of administration; for example, pairing oral targeted therapies with digital adherence programs and leveraging specialty pharmacy networks for complex biologic initiations. Fourth, engage proactively with payers and health technology assessment bodies to co-develop value propositions that emphasize functional outcomes, reduction in flares, and long-term disability avoidance rather than episodic symptom relief. Finally, invest in clinician and patient education to shorten diagnostic delays and support shared decision-making, thereby improving initiation timing and persistence with high-value therapies.

Taken together, these actions form an integrated roadmap that balances clinical innovation with operational readiness and market access acumen, enabling organizations to sustain growth while improving patient outcomes in axial spondyloarthritis.

A multidisciplinary, evidence-weighted methodology combining peer-reviewed science, expert interviews, regulatory analysis, and operational intelligence to produce actionable clinical and commercial insights

This research synthesis draws on a multidisciplinary methodology that integrates primary and secondary sources, expert consultations, and structured evidence appraisal to deliver a comprehensive perspective on axial spondyloarthritis. Clinical and scientific literature, guideline documents, regulatory communications, and peer-reviewed studies provided the foundation for disease biology, therapeutic mechanisms, and safety profiles. These insights were augmented by targeted interviews with clinicians, specialty pharmacists, and market access leads to capture real-world practice patterns, diagnostic workflows, and payer negotiation dynamics.

Supply chain and policy analyses incorporated trade publications, manufacturer disclosures, and logistics partner briefings to assess the operational impacts of tariff changes and distribution constraints. Competitive landscape mapping involved a synthesis of public company disclosures, clinical trial registries, and product labeling to evaluate positioning, development strategies, and lifecycle management approaches. Evidence quality was graded using transparent criteria that emphasized study design, population relevance, and applicability to contemporary clinical practice.

Where possible, synthesis favored longitudinal and comparative data to illuminate differential effectiveness and safety patterns. The methodological approach balanced depth with pragmatic relevance, aiming to produce findings that are both evidence-based and actionable for clinical leaders, commercial strategists, and policy stakeholders.

Synthesize clinical advances, operational resilience, and strategic partnerships into a cohesive approach that accelerates patient-centered outcomes and sustainable access

Axial spondyloarthritis presents both persistent challenges and clear areas of opportunity for clinical innovation and strategic action. Diagnostic delays and heterogenous patient responses continue to complicate care pathways, yet the expanding therapeutic arsenal-including biologics and targeted small molecules-offers new avenues to achieve durable disease control and improve long-term function. Policy developments and trade dynamics introduce operational complexity, but they also motivate beneficial investments in supply resilience, manufacturing diversification, and transparent contracting.

Strategically, successful stakeholders will align robust evidence generation with pragmatic commercialization and access tactics that reflect segment-specific drivers, regional regulatory realities, and evolving payer expectations. Partnerships across the ecosystem-from diagnostics and specialty pharmacies to distribution and digital health providers-can accelerate adoption and optimize patient journeys. Ultimately, the path forward requires coordinated efforts that combine clinical rigor, operational excellence, and a patient-centered focus to translate therapeutic advances into measurable improvements in quality of life for people living with axial spondyloarthritis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of JAK inhibitors for nonradiographic axial spondyloarthritis patients unresponsive to first-line TNF blockers
  • 5.2. Increasing investment in biomarker-driven diagnostics enabling early detection of axial spondyloarthritis progression
  • 5.3. Expansion of telemedicine platforms integrating patient-reported outcomes for remote monitoring of disease activity
  • 5.4. Emergence of bispecific antibody candidates targeting both TNF and IL-17 pathways in pipeline trials
  • 5.5. Growing competition from biosimilar etanercept and adalimumab affecting pricing and market access strategies
  • 5.6. Implementation of quantitative MRI scoring algorithms to improve early diagnosis and treatment stratification
  • 5.7. Adoption of value-based contracting models with payers emphasizing long-term functional outcomes in axial spondyloarthritis biologics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Axial Spondyloarthritis Market, by Product Class

  • 8.1. Conventional DMARDs
    • 8.1.1. Hydroxychloroquine
    • 8.1.2. Methotrexate
    • 8.1.3. Sulfasalazine
  • 8.2. IL-17 Inhibitors
    • 8.2.1. Brodalumab
    • 8.2.2. Ixekizumab
    • 8.2.3. Secukinumab
  • 8.3. JAK Inhibitors
    • 8.3.1. Filgotinib
    • 8.3.2. Tofacitinib
    • 8.3.3. Upadacitinib
  • 8.4. NSAIDs
    • 8.4.1. Diclofenac
    • 8.4.2. Ibuprofen
    • 8.4.3. Naproxen
  • 8.5. TNF Inhibitors
    • 8.5.1. Adalimumab
    • 8.5.2. Certolizumab
    • 8.5.3. Etanercept
    • 8.5.4. Golimumab
    • 8.5.5. Infliximab

9. Axial Spondyloarthritis Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Axial Spondyloarthritis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Axial Spondyloarthritis Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Intravenous
  • 11.3. Oral

12. Axial Spondyloarthritis Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Axial Spondyloarthritis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Axial Spondyloarthritis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Axial Spondyloarthritis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Novartis AG
    • 16.3.3. Janssen Biotech, Inc.
    • 16.3.4. Eli Lilly and Company
    • 16.3.5. UCB S.A.
    • 16.3.6. Amgen Inc.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRI